Event Gaps: Perplexity's picks for 2026-10-16
Perplexity picked HIMS, TSLA, TRV, TFC, FITB for a 1-day horizon. Intraday alpha vs SPY: -0.02%. Picks with positive alpha: 80%.
| Experiment | Event Gaps |
|---|---|
| Model | Perplexity |
| Prompt version | event-gap-v13 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-16 |
| Measured to | 2026-10-19 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -0.02% |
| Picks with positive alpha | 80% |
| Benchmark return | -0.55% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | HIMS | -4.94% | -4.94% | 62% | -4.39% | No | |
| 2 | TSLA | +0.28% | -0.28% | 55% | +0.27% | Yes | |
| 3 | TRV | +0.01% | +0.01% | 58% | +0.56% | Yes | |
| 4 | TFC | -2.11% | +2.11% | 54% | +2.66% | Yes | |
| 5 | FITB | +0.24% | +0.24% | 50% | +0.79% | Yes |
The model's market view
Equities enter the one-session window with earnings momentum but elevated AI-hardware volatility. I favor event-driven dispersion: a reported earnings beat at Travelers, a policy-driven rebound in Hims & Hers, and anticipation of Fifth Third's Monday report, while fading Tesla's post-Roadster enthusiasm and Truist after its reported revenue and EPS miss.
Why each pick
HIMS
Hims & Hers is the highest-conviction event trade: an FDA proposal to allow temporary compounding of certain peptides, including BPC-157, has been sent for White House review. This is an observed policy-development catalyst, not a final rule; Leerink's cited estimate of a $2.2 billion annual telehealth market, with roughly 20% potentially accruing to HIMS, is an analyst expectation rather than reported revenue. The stock rose about 6% on October 15 and was indicated near $29.60 intraday on October 16, suggesting meaningful anticipation is already priced in; continuation depends on further policy headlines rather than a completed regulatory decision. The strongest counter-evidence is that the proposal remains subject to White House review and safety concerns were noted by FDA scientists, so a delay or negative headline could reverse the move quickly. Verified completed daily OHLC history and 20-session high/low/volume statistics were not available from the sources consulted, so those figures are reported as null rather than estimated. Latest quote: $29.605 at 2026-10-16T10:02:00-04:00, live intraday, from Moomoo. Invalidation: a sustained break back below the October 16 intraday low near $29.03 would undermine the rebound thesis.
TSLA
Tesla unveiled its next-generation Roadster on October 15, and the shares initially jumped about 5% in reaction reports. This is an observed product event, but its direct earnings impact is unquantified and the reveal is a sentiment catalyst rather than a near-term fundamental change. The stock closed October 15 at $362.44 after falling 1.29%, then traded near $365.30 intraday on October 16, indicating the announcement pop has largely faded; I expect continued giveback as investors refocus on valuation, AI-hardware volatility, and Tesla's recent earnings miss reported by TradingView. The strongest counter-evidence is that the shares stabilized above the prior close intraday, so enthusiasm has not fully unwound. Verified completed daily OHLC history and 20-session high/low/volume statistics were not available from the sources consulted, so those figures are null. Latest quote: $365.30 at 2026-10-16T10:22:00-04:00, live intraday, from Barchart. Invalidation: a move above the post-announcement intraday high would challenge the fade thesis.
TRV
Travelers reported third-quarter net income of $1.917 billion on October 16, an observed earnings catalyst, and held its results call at 9:00 a.m. ET. The reported profit supports a positive fundamental reassessment, while the stock's October 15 close of $383.89 was already up 1.61%, indicating some pre-earnings strength. I expect a modest further gain as the market digests underwriting and investment results, though the exact consensus comparison was not verified in the available sources, limiting conviction. The strongest counter-evidence is that the shares closed near the upper part of the October 15 range, so a beat may already be partly reflected. Verified completed daily OHLC history and 20-session high/low/volume statistics were not available from the sources consulted, so those figures are null. Latest verifiable quote: $383.89 at the October 15 regular-session close, delayed prior close, from Yahoo Finance; no reliable live October 16 quote was available at answering time. Invalidation: a reversal below the October 15 low of $375.96 would invalidate the continuation thesis.
TFC
Truist reported Q3 EPS of $1.16 versus a $1.17 Zacks consensus and revenue of $5.19 billion, missing consensus by 2.19%; these are observed results. Despite the miss, Yahoo showed the stock at $46.57, up 2.19%, at the October 15 close, which likely reflects broader bank-sector strength rather than the earnings outcome; that creates vulnerability to a post-earnings reassessment during the current session. I expect a modest decline as the reported revenue and EPS shortfall outweighs sector momentum. The strongest counter-evidence is the strong prior-close gain and high liquidity, which could support a sector-driven rebound. Verified completed daily OHLC history and 20-session high/low/volume statistics were not available from the sources consulted, so those figures are null. Latest verifiable quote: $46.57 at the October 15 regular-session close, delayed prior close, from Yahoo Finance; no reliable live October 16 quote was available at answering time. Invalidation: a sustained move above $47 would challenge the downside thesis.
FITB
Fifth Third is an anticipation trade: Schwab and Reuters identify Q3 earnings as officially expected on Monday, October 19, within the forecast window. No results have been reported, so the expected move is based on positioning ahead of the release rather than observed fundamentals. Regional banks have shown strength this week, and FITB closed October 15 at $50.35, up 1.43%, suggesting constructive pre-earnings sentiment; I expect a modest continuation into the report. The strongest counter-evidence is that the stock is near recent highs and any disappointment versus peer results could trigger a sharp reversal. Verified completed daily OHLC history and 20-session high/low/volume statistics were not available from the sources consulted, so those figures are null. Latest verifiable quote: $50.35 at the October 15 regular-session close, delayed prior close, from Yahoo Finance; no reliable live October 16 quote was available at answering time. Invalidation: a reversal below the October 15 intraday area around $49.60 would weaken the pre-earnings continuation thesis.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| Muse Spark 1.1 | TRV, TFC, MTB, NFLX, GM | +0.28% | 60% |
| Gemini 3 Pro | NFLX, TSLA, AMD, BAC, NVDA | -0.45% | 60% |
| Grok 4.5 | AA, TSLA, RF, TFC, CRWV | -0.40% | 40% |
| GPT-6 | CLF, CRWV, TSLA, MAN, FITB | +3.47% | 100% |
| DeepSeek | MTB, TRV, TFC, TSLA, IBRX | +2.09% | 60% |
Written up on ForecastNest Insights: Event Gaps: Perplexity's picks for 2026-10-16.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.